Shangya Technology Co., Ltd. (TPEX:6130)
39.50
+2.45 (6.61%)
Feb 11, 2026, 1:33 PM CST
Shangya Technology Revenue
Shangya Technology had revenue of 39.15M TWD in the quarter ending September 30, 2025, a decrease of -29.78%. This brings the company's revenue in the last twelve months to 159.78M, down -22.61% year-over-year. In the year 2024, Shangya Technology had annual revenue of 195.35M, down -15.47%.
Revenue (ttm)
159.78M
Revenue Growth
-22.61%
P/S Ratio
10.95
Revenue / Employee
5.15M
Employees
31
Market Cap
1.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 195.35M | -35.76M | -15.47% |
| Dec 31, 2023 | 231.12M | 145.95M | 171.36% |
| Dec 31, 2022 | 85.17M | -18.65M | -17.96% |
| Dec 31, 2021 | 103.82M | -34.06M | -24.70% |
| Dec 31, 2020 | 137.87M | 74.40M | 117.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Cowealth Medical Holding | 3.41B |
| Chi Sheng Pharma & Biotech | 1.36B |
| GeneFerm Biotechnology | 654.88M |
| Genomics BioSci & Tech. | 607.89M |
| Tien Liang BioTech | 467.02M |
| Taiwan Biomaterial | 203.27M |